3. HEALTH, SAFETY AND ENVIRONMENTAL PROTECTION

Size: px
Start display at page:

Download "3. HEALTH, SAFETY AND ENVIRONMENTAL PROTECTION"

Transcription

1 1. PURPOSE It is the goal of UCB, Inc. (UCB) to ensure that its marketing and promotional activities comply with all applicable state and federal laws. In addition, UCB endeavors to conform to pertinent industry guidance, including the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals, the U.S. Department of Health and Human Services Office of the Inspector General (OIG) Guidance to the pharmaceutical industry, and the Accreditation Council for Continuing Medical Education (ACCME) standards for industry support of continuing medical education. This SOP describes the policies and procedures to be followed in initiating, documenting, and obtaining reimbursement for UCB external promotional peer-to-peer programs conducted by health care professionals (HCPs). 2. SCOPE This SOP applies to all external promotional peer-to-peer programs run by, or on behalf of, any UCB business unit. 3. HEALTH, SAFETY AND ENVIRONMENTAL PROTECTION There are no significant hazards or special instructions relating to the arrangements described that need to be detailed in this SOP. 4. RESPONSIBILITIES Professional Education Oversight of third party vendor contracted with UCB who will provide a centralized electronic system through which all peer-to-peer programs are administered. Administration of promotional peer-to-peer programs in collaboration with contracted third party which can include maintenance of speaker contracts/ training forms/ CVs, approval of the final program expenditures, and other related activities required to align with UCB policies. Reviewing all annual program plans and providing operational feedback. Sales and Other Field Employees Scheduling and executing promotional peer-to-peer programs events in accordance with UCB Compliance policies, which includes collaborating with the contracted third party vendor on selection of an appropriate venue(s), providing approved invitations to prospective attendees, attendee pre- registration, properly documenting all program attendees, submission of required final promotional peer-to-peer program Page 1 of 16

2 documentation, and reporting any non-compliant activity within 48 hours of program completion. Compliance Reviewing promotional peer-to-peer program plans and providing approval. Reviewing speaker payment amounts for alignment with established FMV rates. Reviewing sales representative program evaluation forms for activities that did not meet compliance requirements. Identifying specific policy violations and ensuring appropriate follow-up activity to address the violation. Monitoring a sample of promotional peer-to-peer programs and related program management activities including earnings reviews of speakers. Business Unit Bureau Managers Developing annual promotional peer-to-peer program plans and documenting midyear program revisions. Obtaining review and approvals for all promotional peer-to-peer program plans and revisions from the Business Unit Management team (with corresponding Compliance/Legal support), Compliance, and Professional Education Developing a list of recommended speakers based on pre-determined criteria. Developing compensation rates for each speaker consistent with approved fair market value ranges. Maintaining promotional peer-to-peer program content and ensuring timely training of speakers on the Review Committee approved content Collaborating with third party vendor to manage designated components of the promotional peer-to-peer program processes. Medical Affairs Reviewing and approving the qualifications of nominated speakers. Review Committee Reviewing and approving promotional peer-to-peer program content and related materials. Page 2 of 16

3 5. PROCEDURE 5.1 Key Procedural Points In addition to following the procedures set forth in this SOP, promotional peer-to-peer programs must also comply with all UCB policies and procedures governing the engagement of HCPs. Please refer to SOP/Policy: U.S. Compliance - Engaging HCPs, HCIs, and Patients/Caregivers in Fee For Service Arrangements and U.S. Fair Market Value. All promotional peer-to-peer programs shall promote the business objectives of UCB and shall comply with all applicable laws and regulations. UCB will approve only promotional peer-to-peer programs that have an appropriate business purpose and need. UCB is responsible for the content of promotional peer-to-peer programs. All materials used in association with peer-to-peer programs must be approved by the Review Committee. Therefore, speakers must use only UCB-approved slides which must be provided to and presented by speakers in their entirety. UCB will train speakers on how to appropriately respond to unsolicited off-label questions. Promotional peer-to-peer presentations must be consistent with FDA-approved product labeling, maintain fair balance between information on safety and efficacy, be truthful and non-misleading and avoid comparative claims concerning competing products in the absence of substantiated evidence supporting the comparison. Speaker contracts must be signed prior to a speaker participating in speaker training or any promotional peer-to-peer programs. Promotional peer-to-peer program related documentation will be maintained in a central repository under the direction of Professional Education. 5.2 Procedural Requirements for Promotional Peer-to-peer Program Annual Plans Each Business Unit that intends to conduct promotional peer-to-peer programs will create an annual plan for engagement of HCPs. Each plan will contain, at a minimum, the following information: Business/strategic objectives and targets Corresponding types programs needed to achieve the business objectives (e.g., peer to peer, web conference) Number of promotional peer-to-peer programs planned Page 3 of 16

4 Number of speakers and specialties required to satisfy program needs The methodology for determining the appropriate number of speakers must take into account legitimate business needs, including anticipated budget, minimum number of speaking engagements required per speaker and speaker compensation caps Anticipated budget associated with program for the twelve month period Estimated training dates and training activities Compensation range for speakers based on established criteria Each annual plan will be reviewed by Professional Education and approved by the Compliance Department. Significant Modifications to annual plans must be approved by the Compliance Department Request and Approval of Promotional Peer-to-Peer Program All peer-to-peer program requests must be managed through a centralized electronic system which will be overseen by Professional Education but may be administered by an approved third party vendor. Programs must comply with all requirements identified in this and related UCB policies and procedures. Following approval of the annual plan, sales and other field employees will complete a program request form, or comparable third party vendor substitute, for each proposed promotional peer-to-peer program. The program request form will include the following information: The substantive nature of the program including the program type The proposed promotional peer-to-peer program topic, including planned meals and venue Promotional Peer-to-Peer Program Content The UCB Review Committee must approve all promotional peer-to-peer program content, handouts and visual aids (i.e., slides) that are to be used by a UCB speaker for a program. Promotional peer-to-peer presentations must be consistent with the product labeling, maintain fair balance between information on safety and efficacy, be truthful and non-misleading, and avoid comparative claims concerning competing products in the absence of substantial evidence supporting the comparison. Content should clearly indicate that the program is sponsored by UCB and that the speaker has been compensated by UCB. Appropriate disease state awareness content must be presented in the approved format, with a clear break between the presentation of such disease awareness content and product messages. All disease state awareness material must be Page 4 of 16

5 consistent with the approved indication for the product that is the subject of the promotional peer-to-peer program. Promotional peer-to-peer program content will be developed for attendees who are likely to utilize the UCB product within its approved uses, as opposed to attendees who would be likely to use the product significantly for off-label uses Speaker Selection for Promotional Peer-to-Peer Bureau Generally, speaker recommendations will be solicited not more than twice a year. Business Unit Bureau Manager will develop a list of speakers based on predetermined criteria. Nominated speaker(s) requires review and approval by the Medical Affairs Department before the nominee may be selected to participate in the designated UCB promotional peer-to-peer bureau. Speakers must be selected based on their clinical expertise in a particular therapeutic area and/or product category, public speaking skills and previous public speaking experience. Speakers may not be selected, in whole or in part, based on an explicit or implicit understanding, hope, or desire that they will prescribe, purchase, or recommend UCB products as a result of participation in the speaker training or to reward speakers for past business or recommendations. Promotional speaking opportunities may not be marketed or used as a venue for solicitation of referrals for speakers. Professional Education, in coordination with the third party vendor, will verify the speaker s credentials, exclusions and debarment status and obtain approvals of the speaker s CV. Speaker CVs will be routed to Medical Affairs for approval to ensure that the candidate has the appropriate scientific and medical qualifications to deliver the promotional peer-to-peer presentation. A W-9 form will be obtained to report compensation. A background check will be completed to ensure that a candidate is not included on an exclusion or debarment listing. Each speaker must sign a contract using the UCB legally approved template inclusive of all compensation rates. Any changes to the contract language must be reviewed and approved by the Legal Department. Professional Education must receive a signed contract from the speaker before he or she may participate in a UCB speaker training program. Upon approval of a candidate and collection of required documentation, selected speakers must complete a UCB speaker training program (refer to SOP Promotional Peer-to-Peer Speaker Bureau Training) before being included in the bureau. Page 5 of 16

6 The size of the speaker bureau for a product s promotional peer-to-peer program should not exceed the number reasonably needed to conduct the planned number of programs. Annually, or more often if required, speaker utilization will be reviewed to ensure that the appropriate number of speakers are active in the bureau and that each speaker is fulfilling the minimum number of programs to remain an active speaker.. Speakers that do not meet the minimum program requirements will be removed from the program, unless an exception request approved by UCB Compliance. The Business Unit Bureau Managers have discretion in purging speakers based on other criteria (e.g., poor presentation skills, lack of availability, changing business needs). Professional Education will be notified of all changes to the promotional peer-topeer speaker bureau. Speakers not meeting contract requirements lose eligibility for contracting for one year, unless UCB Compliance exception request is granted Speaker Responsibilities Each speaker will be appropriately trained on the program content and their individual responsibilities as a UCB promotional speaker. Training must be completed before a speaker engages in a promotional peer-to-peer program for UCB. Speakers must disclose that they are a paid speaker for UCB and are speaking on behalf of the Company. Speakers are responsible for ensuring that approved indications and all necessary safety and risk information included in materials is appropriately presented during the presentations. Product efficacy and safety information must be presented in the same manner and with comparable prominence. Speakers may never proactively provide off-label information. A speaker may answer an unsolicited off-label question only after the conclusion of a program, in a private manner, consistent with current UCB guidance and training. Extensive questions about off-label uses or questions that the speaker cannot answer should be referred to the Medical Affairs Department Written Agreements All speakers must have an executed speaker agreement on file with Professional Education prior to beginning speaker training. All speaker agreements must include the following: the HCP s name; the term/date of the agreement; Page 6 of 16

7 the requirement that the speaker receive training prior to any speaking engagement; a statement that the HCP s participation as a UCB promotional speaker is not intended as an inducement to, and is in no way contingent upon, the health care professional s future use of UCB products; an acknowledgment that the speaker will disclose to the audience UCB s sponsorship of the program; an acknowledgment that the speaker will use only UCB-approved slide decks, outlines, and informational materials as part of any speaking engagement and that representative will make available the FDA-approved prescribing information for all UCB products that are discussed at a promotional peer-topeer program; and an acknowledgment that the content of all presentations will be consistent with the approved labeling for any products discussed at the promotional peer-topeer program. If the Speaker makes any changes to the Legal-approved template speaker agreement, such changes must be reviewed and approved by Legal before agreeing to or executing the agreement Speaker Compensation and Expenses Compensation All compensation paid to speakers should be based on the pre-determined rate structure set forth in UCB s Fair Market Value Analysis. Any deviations from this rate structure must be documented and approved in advance by Compliance. Please refer to Fair Market Value SOP for more information regarding how to comply with this section. Speakers must have a valid and signed speaker contract in order to receive compensation for speaking. UCB will establish an annual calendar year earning cap on speaker compensation which will be included in the annual program plans. Speakers who have reached the annual cap may not be used until the next calendar year. All speaker fees and other forms of payment for promotional peer-to-peer programs must be paid directly to the party who is contracted to render such services for UCB. Payments may not be made to third-party organizations (corporation or charity) as an alternative to paying the speaker directly. In rare cases, a speaker s terms of employment may require that funds be paid to his employer. UCB will consider these on an exception basis and will require written documentation from the speaker and the employer. If accepted, the speaker contract will be jointly executed with the employer. All earnings Page 7 of 16

8 will be tracked to the speaker for earning cap review and transparency reporting. Payments will be monitored by the third party vendor, who will provide notices to Professional Education and the Business Unit Program Manager when a speaker is approaching the cap based on completed and projected programs. Reimbursement for Program Cancellations Live Events No speaker fee will be paid to a speaker for a program cancelled 72 hours (3 business days) or more prior to the previously scheduled program. A speaker fee is payable to the speaker if the program is cancelled by UCB less than 72 hours (3 business days) prior to the previously scheduled program. On-site Electronic Delivery Programs (e.g., typically web-based events) No speaker fee will be paid to a speaker for a program cancelled 36 hours (1.5 business days) or more prior to the previously scheduled program. Speaker fee is payable to the speaker if the program is cancelled by UCB less than 36 hours (1.5 business days) prior to the previously scheduled program. Reimbursement for Travel/Other Expenses UCB may pay for the reasonable travel, lodging, and meal expenses of speakers as set forth in the Policy for Reimbursement included with each speaker contract. UCB will not pay for the travel, incremental lodging, meals, or other expenses of anyone accompanying a speaker. All expenses are considered reportable transactions Program Venues and Expenses Venue for Promotional Peer-to-peer Programs Peer-to-peer programs must be held in locations that are conducive to the business purpose of the meeting. The venue should not be selected based on the existence or quality of amenities, but rather upon proximity to attendees or transportation, quality and cost of meeting rooms and business support, and other business related factors. Resorts or luxury hotels are not appropriate venues. Recreation and entertainment of any type is strictly prohibited in connection with promotional peer-to-peer programs. Page 8 of 16

9 Meals provided in coordination with a promotional peer-to-peer program should be generally modest by local standards by should not exceed the following limits, inclusive of beverage, tax and tips and any other non-overhead fees: Breakfast: $25 per person Lunch: $50 per person Dinner: $125 per person Additional information regarding venue and meals is set forth in the policy Meals and Gifts for Healthcare Professionals and Customers Peer-to-peer Program Execution and Attendance In order to conduct a promotional peer-to-peer program, the sponsoring employee should have confirmed attendance as follows: Live promotional peer-to-peer programs (on-site/off-site): At least two HCPs must be confirmed to be in attendance at least 96 hours (4 business days) prior to the program. If fewer than two HCPs have been confirmed at least 96 hours prior to the program the program must be cancelled and the speaker notified. If two or more HCPs confirmed prior to the 96 hour program window but the actual number in attendance is fewer than expected, a program may still take place with the reduced attendance and confirmed attendees identified on post-event paperwork as a no-show. On-site electronic delivery programs (e.g., typically teleconference, web conference): Based on the program type, at least one HCP must be confirmed in attendance 48 hours prior to the program. The program must be cancelled and the speaker notified if no attendees are confirmed at least 48 hours prior to the program. UCB sales and promotional personnel must use a sign-in sheet at all programs for confirmed or expected attendees. All attendees, inclusive of UCB employees and speaker, are required to sign in upon arrival. Non-electronic attendance forms must be legible when submitted. HCPs are generally allowed to attend up to 2 programs each year for a product presentation unless significant changes/developments occur with the product label and corresponding promotional peer-to-peer program content, in which case, additional invitations may be issued to refresh the HCP s product education. Page 9 of 16

10 Program Management and Evaluations In the event that a speaker presents unapproved content, fails to present the approved content requested by UCB, proactively discusses off-label information about a UCB product, or fails to follow any other applicable policies, the program sponsor (or other Company employee in attendance) must correct such issues during the Program. The sponsoring employee or other UCB representative should address the audience and clarify the approved uses of the product and explain that UCB does not endorse any off-label use. At the conclusion of the program, the program sponsor or other UCB employee should reiterate the speaker s responsibility to remain on-label during the program. The incident must be reported to Compliance. The speaker s failure to comply with UCB policies should be noted in the program evaluation form completed by the UCB representative Program evaluations will be completed by the UCB employee sponsoring the program for each promotional peer-to-peer event.. These evaluations are internal and speaker payments are not dependent on the results of this evaluation. The evaluations are designed to elicit feedback on the overall quality of the program, the presentation by the speaker, compliance concerns and any other information required by the Business Unit. This evaluation will serve as a certification that the program was held in accordance with all applicable company policies and that the speaker remained on-label and appropriately handled any unsolicited requests for off-label information. In the event that an incident is noted, a notice will immediately be sent to Compliance for review and investigation, as appropriate. Evaluations should be monitored by the Product Teams for program effectiveness and for needed follow-up training with HCP speakers on skills, messaging, and/or compliance. Evaluations will be collected, reviewed and retained by the Professional Education office, or with the third party vendor, with all other program related documentation. If evaluations reveal that a speaker has multiple instances of non-compliance despite having received follow-up training, that speaker may not be used in the future. Page 10 of 16

11 Documentation, Record Maintenance and Retention All records, information and deliverables related to this procedure will be retained for a period of six (6) years or longer if required by applicable law, contract or regulatory requirement. Records related to this procedure will be maintained by the activity owner unless otherwise specifically directed by the Legal Department. For GxP records retention refer to Corporate SOP Retention Periods for GxP Records. Promotional peer-to-peer program documentation will be maintained in a central repository by Professional Education. Professional Education, in conjunction with the third party vendor (where applicable), will maintain a system to document and track promotional peer-topeer program,, including receipt of required documentation and payment of fees and expenses. Speaker fees and expenses will be disclosed as required by federal and state law. HCPs may not condition their agreement to speak on UCB s behalf on the nondisclosure of this information. For all promotional peer-to-peer programs, Professional Education will maintain all contracts, evidence of training and CVs from the speaker and ensure that the speaker has been approved by the Medical Affairs Department. The most current version of the consulting agreement template for promotional peer-to-peer programs should be used and will be maintained by the Legal Department Third Party vendors The UCB standard written agreement for third party vendor services will be used to promote consistency between third party vendors who provide services for UCB promotional peer-to-peer programs. Third party vendors will be contractually required to comply with UCB policies, applicable laws and regulations, and industry guidelines (e.g., PhRMA Code), and UCB will retain the right to audit third party vendor performance upon reasonable request and whenever an issue requiring further inquiry is identified. Third party vendors will execute the administration of promotional peer-to-peer programs in accordance with the terms of their contracts and according to UCB procedures. Third party vendors may substitute their own written or electronic forms that comply with the requirements of this procedure following approval by UCB. UCB will be provided access to all systems and vendor forms with a copy of any required documentation to be retained by Professional Education. a) Third Party Vendor Documentation Professional Education will adhere to the following process to document that third party vendors are compliant with relevant UCB SOPs: Page 11 of 16

12 Maintain a system that tracks and ensures that all third party vendors have an agreement with UCB, except where the third party vendor has been contracted by a co-promotion partner. Certify that all required documents (speaker contracts, speaker CV, speaker invoice, and speaker attendee lists) and payment information have been received by UCB. All information relating to each promotional peer-to-peer program, including aggregate financial information must be tracked in order to ensure the Company is able to comply with applicable laws and regulations. This information is reportable to UCB on a periodic basis and upon reasonable demand. Information that must be tracked includes but is not limited to: Speaker name, identifiers Speaker fees and other expenses Attendee names, addresses, degrees, national prescriber identifier number (if applicable) Meal costs Location of program b) Check Disbursement Process Prior to releasing speaker fees for payment, Professional Education, or third party vendor (where applicable), must receive a signed copy of the speaker invoice, which is included on the speaker expense report, to serve as proof of service delivery. c) Compliance Auditing and Monitoring The Compliance Department shall implement monitoring activities to assess compliance with this SOP. Such monitoring activities shall be revised from time to time as determined by the Compliance Department and will include live monitoring of promotional peer-to-peer program events and training exercises. UCB employees and speakers are required to cooperate fully with the Compliance department in all monitoring and auditing activities. 6. ABBREVIATIONS AND DEFINITIONS Abbreviations and definitions, used in this document, are in accordance with the UCB Glossary. To the extent that these definitions differ from those contained in the UCB Glossary, these definitions will take precedence for the purpose of this policy / procedure. 6.1 Abbreviations FDA Food and Drug Administration HCP Health Care Professional CV Curriculum vitae Page 12 of 16

13 6.2 Definitions Fair Market Value Fair Market Value Analysis Health Care Professional Program Sponsor Third Party Vendor The price, expressed in terms of cash equivalents, at which property would change hands between a hypothetical willing and able buyer and a hypothetical willing and able seller, acting at arm s length in an open and unrestricted market, whether neither is under compulsion to buy or sell and when both have reasonable knowledge of the relevant facts. 1 A centrally managed reference tool consisting of pre-determined rates determined by UCB management to represent FMV compensation for certain types of activities performed by HCPs and HCIs for or on behalf of UCB. The rate structure is based on certain factors such as HCP type (i.e., physician or non-physician), specialty (e.g., primary care practitioner, gastroenterologist, rheumatologist), tier type (i.e., KOL or non-kol), service type (e.g., Advisory Boards, Speaker Training, Research), and program length of time. Any person that is a member of the medical, dental, pharmacy or nursing professions or any other person who, in the course of his or her professional activities, may directly or indirectly prescribe, purchase, supply, recommend, administer or arrange for the use of a medicinal product. The UCB employee who organizes a promotional peer-to-peer program. A company/organization contracted with UCB to perform work/services on behalf of UCB. 7. RELATED DOCUMENTS 7.1 Associated Documents N/A 7.2 References gov , U.S. Fair Market Value sop , Retention Periods for GxP Records sop , Promotional Peer-to-peer Speaker Bureau Training Page 13 of 16

14 sop , U.S. Compliance - Engaging HCPs and HCIs in Fee For Service Arrangements American Society of Appraisers Business Valuation Standards Glossary ; Approved June 2005 Copyright 2005, American Society of Appraisers. 8. LIST OF APPENDICES N/A 9. SOP HISTORY Supersedes SOP(s) (SOP number and version) UCBCOM-SOP sop v1.0 sop v2.0 sop v3.0 sop v4.0 sop v5.0 Migration into MIKADO Periodic revision Changes Removed fr-tmpl as an Associated Document. Will be maintained in the Legal dept. Updated due to changing business requirements. Removed last responsibility for Professional Education (no tracking of earnings, done by Compliance) Retired the annual plan review and approval form (sop-af ). Revised 4 th bullet under section to reflect changing speaker responsibilities. Changed cancellation term to 96 hours. Updated the following sections to reflect changes in business requirements: Section 4.0 Requirements, added: third party vendor to Professional Education and Sales and Other Field Employees Section 5.2.1, removed: Earning cap for each speaker and minimum number of programs required. Removed from last paragraph: the Business Unit Management team, Legal and Professional Education before being provided to. Section 5.2.7, added information for Reimbursement for Program Cancellations. Section 5.2.9, modified to reflect current practice. Section (b), removed: a list of attendee printed names and signatures, the program evaluation and. Page 14 of 16

15 Supersedes SOP(s) (SOP number and version) sop v6.0 Changes Changed Title from Promotional Speaker Programs to Section 6.0 updated definition for HCP Replaced speaker with peer-to-peer throughout the document. Page 15 of 16

16 DOCUMENT APPROVAL ELECTRONIC SIGNATURES Signed by Meaning of Signature Server Date (dd-mmm-yyyy HH:mm:ss TZ) GRAVES Mark Subject Matter Expert Approval 14-Aug :23:20 CEST JEFFORDS SCHENCK Jan Author Approval 19-Aug :53:07 CEST HELLING Douglas Legal Approval 21-Aug :19:33 CEST DAVIS Clive Management Approval 22-Aug :02:48 CEST DHALLA Anisa Subject Matter Expert Approval 09-Sep :15:41 CEST Page 16 of 16

RESPIRONICS, INC. CONTRACTING WITH HEALTHCARE PROFESSIONALS OR PROVIDERS AND REFERRAL SOURCES POLICY

RESPIRONICS, INC. CONTRACTING WITH HEALTHCARE PROFESSIONALS OR PROVIDERS AND REFERRAL SOURCES POLICY Page 1 of 6 RESPIRONICS, INC. CONTRACTING WITH HEALTHCARE PROFESSIONALS OR PROVIDERS AND REFERRAL SOURCES POLICY I. Purpose This document sets forth Respironics, Inc. s ( Company ) policy for engaging

More information

Document Type Doc ID Status Version Page/Pages. Policy LDMS_001_ Effective of 11 Title: Global Policy on Ethical Interactions

Document Type Doc ID Status Version Page/Pages. Policy LDMS_001_ Effective of 11 Title: Global Policy on Ethical Interactions Policy LDMS_001_00145767 Effective 6.0 1 of 11 AstraZeneca Owner Ageborg, Katarina Authors Shah, Himani Approvals Approval Reason Approver Date Reviewer Approval Shah, Himani 2015/04/10 13:40:28 Policy

More information

Code on Global Interactions. with Healthcare Professionals

Code on Global Interactions. with Healthcare Professionals Code on Global Interactions with Healthcare Professionals 2 Table of Contents Introduction... 5 Anti-Bribery Anti-Corruption... 6 Guiding Principles... 7 Promotional Activities... 8 Healthcare Professionals

More information

International Health Care Business Integrity for Third Party Intermediaries

International Health Care Business Integrity for Third Party Intermediaries International Health Care Business Integrity for Third Party Intermediaries Introduction Welcome This is the compliance learning module on Johnson & Johnson s International Health Care Business Integrity

More information

HCP CODE: GLOBAL CODE ON INTERACTIONS WITH HEALTHCARE PROFESSIONALS

HCP CODE: GLOBAL CODE ON INTERACTIONS WITH HEALTHCARE PROFESSIONALS HCP CODE: GLOBAL CODE ON INTERACTIONS WITH HEALTHCARE PROFESSIONALS HCP CODE: GLOBAL CODE ON INTERACTIONS WITH HEALTHCARE PROFESSIONALS PREAMBLE: We, at Galderma, are committed to delivering innovative

More information

University of Mississippi Medical Center Interactions with Industry Representatives

University of Mississippi Medical Center Interactions with Industry Representatives I. Purpose The purpose of this policy is to define limits of activity for industry representatives at the (UMMC) for the protection of patients and for the benefit of faculty and staff. UMMC recognizes

More information

FINANCIAL CONFLICT OF INTEREST POLICY

FINANCIAL CONFLICT OF INTEREST POLICY FINANCIAL CONFLICT OF INTEREST POLICY Individuals who are appointed to serve on ABIM boards or committees are expected to have the American Board of Internal Medicine s (ABIM) mission as their primary

More information

LEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements

LEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements LEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP 2/14 Contents 1 Introduction... 3 2 Purpose... 3 3 Terminology and Definitions...

More information

ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP

ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP Methodological Note to HCP/HCO Disclosure Requirements in the LEO Group including specifications from LEO Pharma A/S Hungarian Company representative Office ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO

More information

LEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements

LEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements LEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP 2/14 Contents 1 Introduction... 3 2 Purpose... 3 3 Terminology and Definitions...

More information

Prevention Of Corruption

Prevention Of Corruption Prevention Of Corruption Global Compliance Table Of Contents Standards Application page 6 Purpose page 5 Scope page 6 Bribery/Improper Payments, page 8 Ethical Business Practices, page 8 Unfair Business

More information

Methodological Note to HCP/HCO Disclosure Requirements in the LEO Group including specifications from LEO Pharma A/S Romania Repressentative Office

Methodological Note to HCP/HCO Disclosure Requirements in the LEO Group including specifications from LEO Pharma A/S Romania Repressentative Office Methodological Note to HCP/HCO Disclosure Requirements in the LEO Group including specifications from LEO Pharma A/S Romania Repressentative Office ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP

More information

ARPIM HCP/HCO DISCLOSURE CODE

ARPIM HCP/HCO DISCLOSURE CODE ARPIM HCP/HCO DISCLOSURE CODE ARPIM CODE ON THE DISCLOSURE OF SPONSORSHIPS AND OTHER TRANSFERS OF VALUE FROM PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)

More information

Global Compliance Policy on Due Diligence and Interactions with Third Party Representatives

Global Compliance Policy on Due Diligence and Interactions with Third Party Representatives Global Compliance Policy on Due Diligence and Interactions with Global Compliance Table Of Contents Purpose page 4 Scope page 5 Application page 5 page 7 Teva's Standards page 8 Representative Standards

More information

Code of Conduct Q&A Questions and Answers (version3) Medicines for Europe. Follow us on

Code of Conduct Q&A Questions and Answers (version3) Medicines for Europe. Follow us on Code of Conduct Q&A Questions and Answers (version3) Medicines for Europe Follow us on Rue d Arlon 50-1000 Brussels Belgium T: +32 (0)2 736 84 11- F: +32 (0)2 736 74 38 www.medicinesforeurope.com 1 Code

More information

Anti-Corruption and Healthcare Compliance Policy. Approved By: Corporate Compliance Effective Date: October 15, 2015

Anti-Corruption and Healthcare Compliance Policy. Approved By: Corporate Compliance Effective Date: October 15, 2015 Anti-Corruption and Healthcare Compliance Policy Approved By: Corporate Compliance Effective Date: October 15, 2015 Table of Contents 1. Purpose... 2 2. Scope... 2 3. Definitions... 3 4. Anti-Corruption

More information

Fifth Annual National Congress on Health Care Compliance. Pharmaceutical Sales and Marketing: Are You Afraid to Look Under the Rocks?

Fifth Annual National Congress on Health Care Compliance. Pharmaceutical Sales and Marketing: Are You Afraid to Look Under the Rocks? Fifth Annual National Congress on Health Care Compliance Pharmaceutical Sales and Marketing: Are You Afraid to Look Under the Rocks? Michael P. Swiatocha February 8, 2002 Agenda Introduction - The US Pharmaceutical

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Pharmaceuticals (Ireland) DAC, Company registration number: 55502 Ireland, Address of

More information

This policy applies to all Napo associates who may provide a meal to a healthcare professional.

This policy applies to all Napo associates who may provide a meal to a healthcare professional. Business Meals with Healthcare Professionals Policy In order to provide an important and meaningful exchange of information and to respect healthcare professionals abilities to manage their schedules and

More information

DOCUMENT HISTORY. Supersedes / Replaces. Version Effective Date Summary of Changes 01 30JUN2016 New Methodological Note

DOCUMENT HISTORY. Supersedes / Replaces. Version Effective Date Summary of Changes 01 30JUN2016 New Methodological Note Document Title Methodological Note EFPIA Disclosure of Transfers of Value to Healthcare Professionals and Organisations in Poland ( Methodological Note on Disclosure ) Document Version 01 Effective Date

More information

Takeda Belgium - Methodological note 2015

Takeda Belgium - Methodological note 2015 Takeda Belgium - Methodological note 2015 Accompanying document for the public transparency of transfer of value to Healthcare Professionals and Healthcare Organisations 1. General introduction... 2 2.

More information

GIFTS, GRATUITIES AND BUSINESS COURTESIES

GIFTS, GRATUITIES AND BUSINESS COURTESIES DEPARTMENT MANUAL Hospital Administrative ORIGINAL 10/02 REVISED 03/09 REVIEWED 03/09 101 East Valencia Mesa Drive, P. O. Box 4138 Fullerton, California, Telephone (714) 871-3280 POLICY/PROCEDURE Department

More information

AstraZeneca AB Södertälje. Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2015 Data in 2016

AstraZeneca AB Södertälje. Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2015 Data in 2016 AstraZeneca AB 556011-7482 151 85 Södertälje Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2015 Data in 2016 Contents 1. Introduction... 4 Approach to disclosure

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca UK Limited Registered in England No 3674842 Registered Office, 2 Kingdom Street, London,

More information

HONORARIA POLICY AND PROCEDURE

HONORARIA POLICY AND PROCEDURE HONORARIA POLICY AND PROCEDURE POLICY DESCRIPTION: continuing medical education Policy Governing Honoraria and Reimbursement of Expenses for physicians, and scientists in the role of invited speakers.

More information

Frequently Asked Questions

Frequently Asked Questions Medical Imaging and Technology Alliance (MITA) Fact Sheet on Federal and State Medical Device Marketing or Sunshine Disclosure Laws Updated November 16, 2011 A new federal law called the Federal Physician

More information

Glossary of Definitions

Glossary of Definitions Glossary of Definitions For purposes of MAPP, the terms listed below have the following meaning: Advisory Board: means a specific type of consultancy engagement where experts are engaged to offer advice

More information

Evaluating and Determining Fair Market Value for KOLs. Presented by Jen Johnson, CFA August 10, 2011

Evaluating and Determining Fair Market Value for KOLs. Presented by Jen Johnson, CFA August 10, 2011 Evaluating and Determining Fair Market Value for KOLs Presented by Jen Johnson, CFA August 10, 2011 Discussion Points I. Introduction II. Physician Payments In the News III. Guidelines to Disclosure IV.

More information

Methodology for Compliance with the ABPI Disclosure Code. Introduction Page 1. General Comments Page 2. Indirect Transfers of Value Page 3

Methodology for Compliance with the ABPI Disclosure Code. Introduction Page 1. General Comments Page 2. Indirect Transfers of Value Page 3 Date Published: 15 th March 2017 Version: 20 (December 4, 2015) Index Methodology for Compliance with the ABPI Disclosure Code Introduction Page 1 General Comments Page 2 Indirect Transfers of Value Page

More information

Gilead Transparency Reporting Methodological Note

Gilead Transparency Reporting Methodological Note Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers

More information

AABB ANNUAL MEETING SPEAKER INFORMATION PACKET Anaheim, CA October 24-27, 2015

AABB ANNUAL MEETING SPEAKER INFORMATION PACKET Anaheim, CA October 24-27, 2015 AABB ANNUAL MEETING SPEAKER INFORMATION PACKET Anaheim, CA October 24-27, 2015 Table of Contents Topic Page Introduction 3 Speaker Responsibilities and Guidelines for Online Information Submission 4 Faculty

More information

CODE OF CONDUCT. Medicines for Europe. Follow us on

CODE OF CONDUCT. Medicines for Europe. Follow us on CODE OF CONDUCT Medicines for Europe Follow us on Rue d Arlon 50-1000 Brussels Belgium T: +32 (0)2 736 84 11- F: +32 (0)2 736 74 38 www.medicinesforeurope.com 1 Contents Code of Conduct 1. Introduction

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Bulgaria EOOD Registration number 201340239 36 Dragan Tsankov, Bulgaria, Sofia1057 Contents

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Österreich GmbH Landstraßer Hauptstraße 1A, 1030 Wien Firmenbuch FN 51184x, HG Wien Contents

More information

Gilead Transparency Reporting Methodological Note

Gilead Transparency Reporting Methodological Note Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers

More information

Travel & Expense Policy

Travel & Expense Policy Travel & Expense Policy Updated: 01/01/2018 203 INDIGO DRIVE, BRUNSWICK, GA 31520 TOLL FREE: (888) 2612671 PHONE: (912) 2612669 FAX: (912) 2610561 www.sepalabs.com Travel & Expense Policy Purpose: SEPA

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 ASTRAZENECA LUXEMBOURG SA N 2002 2220 862 AM BRILL 7B LU-3961 EHLANGE LUXEMBOURG Contents 1. Introduction...

More information

College of Medicine Policy on Pharmaceutical, Medical Device, and Biotechnology. (1) Definitions. The following definitions apply to this regulation:

College of Medicine Policy on Pharmaceutical, Medical Device, and Biotechnology. (1) Definitions. The following definitions apply to this regulation: College of Medicine Policy on Pharmaceutical, Medical Device, and Biotechnology Industry Conflict of Interest (1) Definitions. The following definitions apply to this regulation: (a) COM means the University

More information

Gilead Transparency Reporting Methodological Note

Gilead Transparency Reporting Methodological Note Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers

More information

VENDOR PROGRAM. Vendors must complete the Vendor Screening and Disclosure Form as follows: *must be completed prior to any signed purchase order

VENDOR PROGRAM. Vendors must complete the Vendor Screening and Disclosure Form as follows: *must be completed prior to any signed purchase order VENDOR PROGRAM 1. PURPOSE The purpose of this policy is to outline the standards that the Hospital utilizes in evaluating which vendors to contract with, the standards for contracting, and the code of

More information

ABPI Disclosure Methodological Note March 2017

ABPI Disclosure Methodological Note March 2017 ABPI Disclosure Methodological Note March 2017 This note describes the methods used by Roche in the UK to meet its obligations and the requirements for disclosing payments and Transfers of Value (ToV)

More information

AstraZeneca AB Södertälje. Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

AstraZeneca AB Södertälje. Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca AB 556011-7482 151 85 Södertälje Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents 1. Introduction... 4 Approach to disclosure

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Eesti OÜ Reg. kood 11733875 Järvevana tee 9 11314 Tallinn Estonia Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents 1. Introduction...

More information

Gilead Transparency Reporting Methodological Note

Gilead Transparency Reporting Methodological Note Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca SA 000638901000 4 Theotokopoulou & Astronafton 151 15 Maroussi, Athens, Greece PV: 2290014.1

More information

DOCUMENT HISTORY. Supersedes / Replaces. Version Effective Date Summary of Changes 01 30JUN2017 New Methodological Note

DOCUMENT HISTORY. Supersedes / Replaces. Version Effective Date Summary of Changes 01 30JUN2017 New Methodological Note Document Title Methodological Note EFPIA Disclosure of Transfers of Value to Healthcare Professionals and Organisations ( Methodological Note on Disclosure ) Document Version 01 Effective Date 30JUN2017

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 NV ASTRAZENECA SA BE 0400.165.679 110, rue Egide Van Ophemstraat B-1180 Brussels Belgium Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents

More information

Code of Ethical Business Practice

Code of Ethical Business Practice Code of Ethical Business Practice MECOMED Guidelines on Interactions with Healthcare Professionals & Healthcare Organisations Approved by Mecomed Executive committee, 20 th June 2017 Page 1 of 48 INTRODUCTION...

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Predstavništvo AstraZeneca UK Limited 29004463 15 Bulevar Vojvode Misica, 11 000 Belgrade, Serbia

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 LLC «AstraZeneca Ukraine» Legal address: Kyiv, Hvoiky str. 15/15,04080 Ukraine Actual address: Kyiv,

More information

Compliance, Codes and Communications. Dr Judith Grice

Compliance, Codes and Communications. Dr Judith Grice Compliance, Codes and Communications A practical guide to pharmaceutical marketing in the UK Fifth edition: Covering the 2016 ABPI Code Dr Judith Grice CHAPTER 2 Meetings and Congresses Main clauses: 10,

More information

Gilead Transparency Reporting Methodological Note

Gilead Transparency Reporting Methodological Note Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers

More information

Transfer of Value Disclosure Report as per National Legislation

Transfer of Value Disclosure Report as per National Legislation Merz Pharmaceuticals GmbH Methodological Note Transfer of Value Disclosure Report as per National Legislation 1 I) Introductory note Merz supports laws and obligations which promote transparency around

More information

Methodology for Compliance with the Research-Based Pharmaceutical Industry (LIF) Disclosure Code

Methodology for Compliance with the Research-Based Pharmaceutical Industry (LIF) Disclosure Code Methodology for Compliance with the Research-Based Pharmaceutical Industry (LIF) Disclosure Code Date Published: 31 May 2017 Index Annex 1: The disclosure in accordance with the Schedule 2 Template Annex

More information

Disclosure Methodological Note For Aventis Pharma Ltd trading as Sanofi

Disclosure Methodological Note For Aventis Pharma Ltd trading as Sanofi Disclosure 2015 Methodological Note For Aventis Pharma Ltd trading as Sanofi INTRODUCTION The EFPIA Disclosure Code requires all EFPIA member companies to disclose transfers of value (TOV) such as support

More information

Methodological Note to 2017 Disclosure Report for Aventis Pharma Limited Genzyme Therapeutics Limited and Sanofi Pasteur

Methodological Note to 2017 Disclosure Report for Aventis Pharma Limited Genzyme Therapeutics Limited and Sanofi Pasteur Methodological Note to 2017 Disclosure Report for Aventis Pharma Limited Genzyme Therapeutics Limited and Sanofi Pasteur Job Bag: SAGB.SA.18.03.0294 Date of Preparation: March 2018 INTRODUCTION The European

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Pharma Poland Sp. z o.o. 0000117902 Postepu 14, 02-676 Warsaw Contents 1. Introduction...

More information

CONDUCTING BUSINESS WITH CVS HEALTH

CONDUCTING BUSINESS WITH CVS HEALTH CONDUCTING BUSINESS WITH CVS HEALTH As a vendor/supplier to one or more affiliates of CVS Health, you and your company play an integral part in our success as a pharmacy innovation company. Therefore,

More information

Sanofi-Aventis Bulgaria EOOD Methodological Note

Sanofi-Aventis Bulgaria EOOD Methodological Note Sanofi-Aventis Bulgaria EOOD Methodological Note INTRODUCTION Collaboration between healthcare professionals and Pharmaceutical Companies has long been a positive driver for advancements in patient care

More information

European Board for Accreditation in Hematology Standards & Guidelines

European Board for Accreditation in Hematology Standards & Guidelines European Board for Accreditation in Hematology Standards & Guidelines Standards 1 Only CME activities that exclusively benefit hematologists and their patients are eligible for accreditation. 2 Only academic

More information

Paul Lorenz, MBA Chief Executive Officer, SCVMC. Continuing Medical Education (CME) Standards for Commercial Support

Paul Lorenz, MBA Chief Executive Officer, SCVMC. Continuing Medical Education (CME) Standards for Commercial Support Administrative Policies and Procedures Manual VMC # 154.02 October 5, 2013 TO: FROM: SUBJECT: REFERENCES: SCVMC Employees Paul Lorenz, MBA Chief Executive Officer, SCVMC Continuing Medical Education (CME)

More information

METHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)

METHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) METHODOLOGY NOTES TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) Country of Disclosure: Belgium Year of Disclosure: 2017 for 2016

More information

The Pharmaceutical Industry s Code of Practice on. Promotion etc., of Medicinal Products. aimed at Healthcare Professionals

The Pharmaceutical Industry s Code of Practice on. Promotion etc., of Medicinal Products. aimed at Healthcare Professionals The Pharmaceutical Industry s Code of Practice on Promotion etc., of Medicinal Products aimed at Healthcare Professionals Self-regulation since 1973 The Ethical Committee for the Pharmaceutical Industry

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Latvija 40103252820 Skanstes iela 50, Rīga, LV-1013 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents 1. Introduction... 4 Approach

More information

MONTEFIORE HEALTH SYSTEM ADMINISTRATIVE POLICY AND PROCEDURE

MONTEFIORE HEALTH SYSTEM ADMINISTRATIVE POLICY AND PROCEDURE MONTEFIORE HEALTH SYSTEM ADMINISTRATIVE POLICY AND PROCEDURE SUBJECT: CONFLICT OF INTEREST NUMBER: JH20.1 OWNER: DEPARTMENT OF COMPLIANCE EFFECTIVE: REVIEW/REVISED: SUPERSEDES: 10/15 10/15 CROSS-REFERENCE:

More information

METHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)

METHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) METHODOLOGY NOTES TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) Country of Disclosure: Ireland Year of Disclosure: 2018 for 2017

More information

HKAPI Code of Practice 19 th Edition, 2019

HKAPI Code of Practice 19 th Edition, 2019 Frequently Asked Questions Section 4 Methods of Promotion to Healthcare Professionals 1. Is a gimmick (promotional item) considered a reminder promotion? Per Section 2.1 of the revised Code of Practice,

More information

METHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)

METHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) METHODOLOGY NOTES TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) Country of Disclosure: Austria Year of Disclosure: 2018 for 2017

More information

Corporate Compliance Program Overview

Corporate Compliance Program Overview Corporate Compliance Program Overview Posted as Required by California Health & Safety Code s 119400-119402 Mobius Therapeutics, LLC (Mobius) is committed to conducting business in compliance with federal,

More information

METHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)

METHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) METHODOLOGY NOTES TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) Country of Disclosure: United Kingdom Year of Disclosure: 2017

More information

SCDM s CODE OF ETHICS FOR MARKETING MEDICAL DEVICES

SCDM s CODE OF ETHICS FOR MARKETING MEDICAL DEVICES Scientific Society Medical Device Industry SCDM s CODE OF ETHICS FOR MARKETING MEDICAL DEVICES 1. INTRODUCTION It is necessary that the marketing of medical devices be governed by ethical standards that

More information

Any healthcare professional and healthcare organization whose primary practice, principal professional address or place of incorporation

Any healthcare professional and healthcare organization whose primary practice, principal professional address or place of incorporation METHODOLOGICAL NOTE on the EFPIA disclosure of transfers of value to healthcare professionals and organizations Country: Russia Last Update: 25.04.2018 Version: 02; this document replaces previous drafts

More information

Coming in OptoWest Regional Conferences MARKETING & SPONSORSHIP PLANNER

Coming in OptoWest Regional Conferences MARKETING & SPONSORSHIP PLANNER Coming in 2015 OptoWest Regional Conferences MARKETING & SPONSORSHIP PLANNER Two regional OptoWest meetings featuring innovative education presented in a one full-day format NEW FOR 2015 The California

More information

Novartis Methodological Note

Novartis Methodological Note Novartis Methodological Note on Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of Transfers of Value

More information

DEPARTMENT OF MANAGEMENT SERVICES ADMINISTRATIVE POLICY. TITLE: Management of the Privately Operated Institutions Inmate Welfare Trust Fund (POIIWTF)

DEPARTMENT OF MANAGEMENT SERVICES ADMINISTRATIVE POLICY. TITLE: Management of the Privately Operated Institutions Inmate Welfare Trust Fund (POIIWTF) DEPARTMENT OF MANAGEMENT SERVICES ADMINISTRATIVE POLICY TITLE: Management of the Privately Operated Institutions Inmate Welfare Trust Fund (POIIWTF) EFFECTIVE: March 4, 2009 REVISED: February 1, 2017 POLICY

More information

RULES GOVERNING DRUG INFORMATION

RULES GOVERNING DRUG INFORMATION RULES GOVERNING DRUG INFORMATION As laid down on 15 November 1994 by the General Assembly of the Norwegian Association of Pharmaceutical Manufacturers including later revisions, the most recent at the

More information

Novartis Methodological Note

Novartis Methodological Note Novartis Methodological Note on Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of Transfers of Value

More information

Any healthcare professional and healthcare organisation whose primary practice, principal professional address or place of incorporation

Any healthcare professional and healthcare organisation whose primary practice, principal professional address or place of incorporation METHODOLOGICAL NOTE on the EFPIA disclosure of transfers of value to healthcare professionals and organisations Country: Finland Last Update: 25.04.2018 Version: 02; this document replaces previous drafts

More information

Novartis Methodological Note

Novartis Methodological Note Novartis Methodological Note on Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of Transfers of Value

More information

SECTION: Accounts Payable and Disbursements. SUBJECT: Reimbursement of Expenses When on Society Business (Managing Policy)

SECTION: Accounts Payable and Disbursements. SUBJECT: Reimbursement of Expenses When on Society Business (Managing Policy) 1. Policy Purpose: The Board has approved a Governing Policy for Reimbursement of. The purpose of this managing policy is to provide further direction for staff in order to comply with the Governing Policy.

More information

SAMPLE DOCUMENT. Date: 2011 USE STATEMENT & COPYRIGHT NOTICE

SAMPLE DOCUMENT. Date: 2011 USE STATEMENT & COPYRIGHT NOTICE SAMPLE DOCUMENT Type of Document: Financial Policies & Procedures Museum Name: Alutiiq Museum and Archaeological Repository Date: 2011 Type: Natural History Budget Size: $5 million to $9.9 million Budget

More information

Mitsubishi Tanabe Pharma Group Methodology. Transfers of Value to Healthcare Professionals (HCP) and Healthcare Organisations (HCO) in Europe

Mitsubishi Tanabe Pharma Group Methodology. Transfers of Value to Healthcare Professionals (HCP) and Healthcare Organisations (HCO) in Europe Mitsubishi Tanabe Pharma Group Methodology Transfers of Value to Healthcare Professionals (HCP) and Healthcare Organisations (HCO) in Europe Introduction Under the EFPIA Code on Disclosure of Transfers

More information

The Institute of Internal Auditors. Austin Chapter. Policies and Procedures

The Institute of Internal Auditors. Austin Chapter. Policies and Procedures 1. Polling Board Members by e-mail: The Institute of Internal Auditors Austin Chapter Policies and Procedures The Chapter President, or his/her designee, may poll the Board members by e-mail when a decision

More information

CORPORATE COMPLIANCE: CONFLICT OF INTEREST

CORPORATE COMPLIANCE: CONFLICT OF INTEREST CORPORATE COMPLIANCE: CONFLICT OF INTEREST Conflict of Interest (CC1208) KEY WORDS: Disclosure of Financial Relationships, Conflict of Interest, Human Subjects Research OBJECTIVE/BACKGROUND: Board Members,

More information

Novartis Methodological Note

Novartis Methodological Note Novartis Methodological Note on Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of Transfers of Value

More information

CONTACT INFORMATION ASSOCIATION FEE. Heidi Wingate, CME Coordinator Completed applications received on or before February 7, 2019:

CONTACT INFORMATION ASSOCIATION FEE. Heidi Wingate, CME Coordinator Completed applications received on or before February 7, 2019: A M E R I C A N A S S O C I AT I O N O F C L I N I C A L E N D O C R I N O L O G I S T S 2 8 TH A N N U A L S C I E N T I F I C & C L I N I C A L C O N G R E S S April 24-28, 2019 Los Angeles, California

More information

Changes to the ABPI Code of Practice -

Changes to the ABPI Code of Practice - Changes to the ABPI Code of Practice - from a Medical Education & PR perspective For Network Pharma members Background European (EFPIA) Code updated in 2007 ABPI had to conform by 1st July Plus UK-specific

More information

Novartis Methodological Note

Novartis Methodological Note Novartis Methodological Note on Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of Transfers of Value

More information

Novartis Methodological Note

Novartis Methodological Note Novartis Methodological Note on Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of Transfers of Value

More information

APPLICATION REGULATIONS OF THE CODE OF PRACTICE ON THE PROMOTION OF MEDICINAL PRODUCTS

APPLICATION REGULATIONS OF THE CODE OF PRACTICE ON THE PROMOTION OF MEDICINAL PRODUCTS Association of International Research-based Pharmaceutical Manufacturers Skolas iela 3, Riga, LV 1010 Phone: + 371 29253093 Fax: + 371 67332148 e-mail: siffa@siffa.lv web: www.siffa.lv Latvian Generic

More information

Graduate Medical Education Medical Industry Interaction Policy and Procedure. December 18, 2008

Graduate Medical Education Medical Industry Interaction Policy and Procedure. December 18, 2008 Graduate Medical Education Medical Industry Interaction Policy and Procedure December 18, 2008 Purpose: To ensure that all residents and fellows interactions with representatives of the pharmaceutical

More information

Understanding the Forces Driving Disclosure

Understanding the Forces Driving Disclosure Understanding the Forces Driving Disclosure March 3, 2010 Jeffrey L. Handwerker Forces Behind the Trend Toward Disclosure State Laws/Legislatures/NLARx Academic Institutions Voluntary Changes in Company

More information

Effective Date: 9/09

Effective Date: 9/09 North Shore-LIJ Health System is now Northwell Health POLICY TITLE: Screening of Federal and State Exclusion Lists POLICY #: 800.05 System Approval Date: 7/21/16 Site Implementation Date: Prepared by:

More information

DEPARTMENT OF HEALTH AND HUMAN SERVICES WASHINGTON, DC 2020! June 21, Re: Modification of Advisory Opinion (Request No.

DEPARTMENT OF HEALTH AND HUMAN SERVICES WASHINGTON, DC 2020! June 21, Re: Modification of Advisory Opinion (Request No. (~ " SUl.viCES.V,:::zt. DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF INSPECTOR GENERAL WASHINGTON, DC 2020! OFFICE OF COUNSEL TO THE INSPECTOR GENERAL 330 INDEPENDENCE AVENUE, SW COHEN BUILDING -

More information

Foreign Corrupt Practices Act Policy

Foreign Corrupt Practices Act Policy Page 1 of 8 Foreign Corrupt Practices Act Policy Union Pacific's Values Statement emphasizes high ethical standards to ensure that the Company maintains and enhances its solid reputation as one of America's

More information

EFPIA DISCLOSURE METHODOLOGICAL NOTE JUNE 2016 MALTA IPSEN PRIMA TRANSPARENCY PROGRAM METHODOLOGICAL NOTE - MALTA

EFPIA DISCLOSURE METHODOLOGICAL NOTE JUNE 2016 MALTA IPSEN PRIMA TRANSPARENCY PROGRAM METHODOLOGICAL NOTE - MALTA IPSEN PRIMA TRANSPARENCY PROGRAM METHODOLOGICAL NOTE - 2 Contents 1 PREAMBLE... 4 2 PURPOSE... 6 2.1 Terminology... 6 3 SCOPE OF THE DISCLOSURE... 7 3.1 Recipients... 7 3.1.1 HCP... 7 3.1.2 HCO... 8 3.1.3

More information

Supplemental Special Advisory Bulletin: Independent Charity. Patients who cannot afford their cost-sharing obligations

Supplemental Special Advisory Bulletin: Independent Charity. Patients who cannot afford their cost-sharing obligations Supplemental Special Advisory Bulletin: Independent Charity Patient Assistance Programs I. Introduction Patients who cannot afford their cost-sharing obligations for prescription drugs may be able to obtain

More information

Fair Market Value Implications for Sleep Transactions National Sleep Foundation

Fair Market Value Implications for Sleep Transactions National Sleep Foundation Fair Market Value Implications for Sleep Transactions National Sleep Foundation Presented by: Richard E. Chasinoff, MBA, MHA, AVA, Director March 17, 2011 Discussion Topics 1. Introduction to fair market

More information

EPAP (External Professional Activities for Pay)

EPAP (External Professional Activities for Pay) U N C H E A L T H C A R E S Y S T E M EPAP (External Professional Activities for Pay) External professional activities for pay (EPAP) means any activity that is not included within one's University employment

More information

SUBJECT: Reimbursement of Expenses When on Society Business (Governing Policy)

SUBJECT: Reimbursement of Expenses When on Society Business (Governing Policy) SECTION: BY: Board of Directors (Governing Policy) DATE: March 30, 2007 1. Policy Purpose This policy sets the requirements and practices for the reimbursement of amounts incurred by employees, contractors,

More information